Evidence map›Paper›PMID 33621267›Full record

ArticlePloS one2021

Prevalence and cardiometabolic correlates of ketohexokinase gene variants among UK Biobank participants.

Joseph A Johnston, David R Nelson, Pallav Bhatnagar, Sarah E Curtis, Yu Chen, James G MacKrell

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Joseph A JohnstonGlobal Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, United States of America.ORCID 0000-0003-3913-9256
David R NelsonGlobal Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Pallav BhatnagarLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Sarah E CurtisGlobal Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Yu ChenLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
James G MacKrellLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Eli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Essential fructosuria (EF) is a benign, asymptomatic, autosomal recessive condition caused by loss-of-function variants in the ketohexokinase gene and characterized by intermittent appearance of fructose in the urine. Despite a basic understanding of the genetic and molecular basis of EF, relatively little is known about the long-term clinical consequences of ketohexokinase gene variants. We examined the frequency of ketohexokinase variants in the UK Biobank sample and compared the cardiometabolic profiles of groups of individuals with and without these variants alone or in combination. Study cohorts consisted of groups of participants defined based on the presence of one or more of the five ketohexokinase gene variants tested for in the Affymetrix assays used by the UK Biobank. The rs2304681:G>A (p.Val49Ile) variant was present on more than one-third (36.8%) of chromosomes; other variant alleles were rare (<1%). No participants with the compound heterozygous genotype present in subjects exhibiting the EF phenotype in the literature (Gly40Arg/Ala43Thr) were identified. The rs2304681:G>A (p.Val49Ile), rs41288797 (p.Val188Met), and rs114353144 (p.Val264Ile) variants were more common in white versus non-white participants. Otherwise, few statistically or clinically significant differences were observed after adjustment for multiple comparisons. These findings reinforce the current understanding of EF as a rare, benign, autosomal recessive condition.

Indexed as

AllelesGenetic VariationAgedBiological Specimen BanksFemaleFructokinasesFructose Metabolism, Inborn ErrorsGenotypeHeterozygoteHumansMaleMiddle AgedPhenotypeUnited KingdomFructokinasesketohexokinase

Identifiers

PMID33621267
PMCPMC7901775
OpenAlexW3130974893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.